Trials / Not Yet Recruiting
Not Yet RecruitingNCT07495033
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Interstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis. The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung volume in patients with interstitial lung disease associated with connective tissue disease (CTD-ILD) on the basis of standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telitacicept | Subjects will receive Telitacicept. |
| DRUG | Placebo | The placebo contains no active ingredients. To maintain the blind, the placebo matches the active drug in all physical aspects. |
Timeline
- Start date
- 2026-04-20
- Primary completion
- 2029-05-31
- Completion
- 2030-05-31
- First posted
- 2026-03-27
- Last updated
- 2026-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07495033. Inclusion in this directory is not an endorsement.